Global Nrf2 Pathway Activators Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Nrf2 Pathway Activators Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Nrf2 (nuclear factor erythroid-2-related factor 2) is a transcription factor that activates over 500 genes via molecules called sirtuins. Nrf2 activation can be achieved through exercise, calorie restriction (including fasting) and ingestion of natural nutrients that are NRF2 activators.

Market Overview:

The latest research study on the global Nrf2 Pathway Activators market finds that the global Nrf2 Pathway Activators market reached a value of USD 6120.95 million in 2022. It’s expected that the market will achieve USD 7848.29 million by 2028, exhibiting a CAGR of 4.23% during the forecast period.

Influence of COVID-19 Outbreak on Nrf2 Pathway Activators Industry Development

Clinical trials are an extremely important part of life science research. Only through clinical trials can products enter the market and become commodities. The epidemic has caused an irreversible obstacle to a large number of enterprises, and will also pose a huge challenge to the Nrf2 Pathway Activators industry.

Initially, during the COVID-19 period, all R&D and production resources are concentrated on the production of anti-epidemic drugs and vaccines and other related products. In a short period of time, the production and R&D of the Nrf2 industry may be ignored. In addition, the second wave of epidemics once again reached Europe and North America, and the number of hospitalizations and deaths due to COVID-19 is also increasing rapidly. In response to the recurrence of the epidemic, European and American countries are stepping up their efforts to prevent the epidemic, and stricter epidemic prevention and control measures will be implemented again. Strict epidemic prevention and control measures will affect the flow of people and activities, and in turn affect logistics, causing the production of the pharmaceutical industry to be impacted due to the supply of raw materials and labor shortages.

Market Driver Analysis

Oxidative stress is induced by the imbalance of the redox state in the body and involves excessive accumulation of reactive oxygen species (ROS) or dysfunction of the antioxidant system. In the short term, oxidative stress is unlikely to be harmful, because although the body may be temporarily overwhelmed, it usually responds and removes any harmful compounds. However, chronic oxidative stress is associated with a variety of diseases, including Parkinson's disease, Alzheimer's disease, cardiovascular disease, and several types of cancer.

Take Alzheimer's disease as an example. Numerous studies have shown that compared with normal brains, the content of Nrf2 in the brain of Alzheimer's disease patients decreases, and the oxidative stress increases significantly. Oxidative stress can cause the deposition of amyloid in the brain, and Apeptide deposition can aggravate oxidative stress, leading to the occurrence and development of Alzheimer's disease. The Keap1-Nrf2-ARE signaling pathway is an important regulatory pathway for maintaining redox homeostasis in the body. Nrf2 activators can increase the content of Nrf2 in the brain, induce the transcription of cytoprotective genes, reduce oxidative stress, and improve the symptoms of Alzheimer's disease. It can be used as a treatment for Alzheimer's. Candidate compounds for the disease. Only a more comprehensive and in-depth development of Nrf2 study can more effectively develop new drugs for the treatment of Alzheimer's disease. With the increasing incidence of such OS diseases, Nrf2 pathway activators will also receive more and more attention.

Some scientists believe the transcription factor nrf2 regulates levels of antioxidant proteins, a part of the response to everyday cellular stress, such as that induced by raised mitochondrial activity and greater generation of reactive oxygen species (ROS) during exercise. Greater nrf2 activity shows up in long-lived species and in the modest slowing of aging that can be achieved via hormesis in some species. So the R&D about the Nrf2 pathway activators will earn more attention in the forecast period, which will largely help the development of the Nrf2 activators industry.

Awareness of anti-cell-senescence from the increasing geriatric population across the world and generation Y have been raise. And the awareness has been accelerating many anti-aging products' development.

Some scientists believe the transcription factor nrf2 regulates levels of antioxidant proteins, a part of the response to everyday cellular stress, such as that induced by raised mitochondrial activity and greater generation of reactive oxygen species (ROS) during exercise. Greater nrf2 activity shows up in long-lived species and in the modest slowing of aging that can be achieved via heresies in some species. So the R&D about the Nrf2 pathway activators will earn more attention in the forecast period, which will largely help the development of the Nrf2 activators industry.

Region Overview:

North America had the highest growth rate of all regions.

Company Overview:

Biogen is one of the major players operating in the Nrf2 Pathway Activators market, holding a share of 82.23% in 2020.

Biogen Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company products address diseases such as multiple sclerosis, non-hodgkin's lymphoma, rheumatoid arthritis, crohn's disease, and psoriasis.

Reata Pharmaceuticals, Inc. operates as a biopharmaceutical company. The Company focuses on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with various life-threatening diseases.

Segmentation Overview:

Among different product types, Dimethyl Fumarate segment is anticipated to contribute the largest market share in 2027.

Application Overview:

By application, the Pharmaceutical segment occupied the biggest share from 2017 to 2022.

Key Companies in the global Nrf2 Pathway Activators market covered in Chapter 3:

Biophore
Reata Pharmaceuticals
Cayman Chemical Company
BioVision Inc
Biogen
Abcam
BOC Sciences

In Chapter 4 and Chapter 14.2, on the basis of types, the Nrf2 Pathway Activators market from 2018 to 2029 is primarily split into:

Dimethyl Fumarate
4-Octyl Itaconate
Bardoxolone
Other

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Nrf2 Pathway Activators market from 2018 to 2029 covers:

Pharmaceutical
Laboratory

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)